心血管疾病的基因和基因组测试:美国心脏协会的政策声明
Circulation
|November 13, 2025
概括
基因组医学有助于心血管保健, 但政策更新对于公平获取基因检测和道德数据使用至关重要. 战略投资和多学科方法是优化效益和降低风险的关键.
科学领域:
- 心血管医学
- 基因组学
- 卫生政策
背景情况:
- 基因组学和精确医学对于诊断,分层风险和管理心血管疾病越来越重要.
- 扩大基因测试可访问性需要更新公平实施,监管和数据管理的政策.
研究的目的:
- 为基因和基因组技术在心血管医学中的公平和道德实施提供政策框架.
- 解决关键政策领域,包括联邦法规,数据隐私,报销和新兴技术的整合.
主要方法:
- 美国心脏协会的政策声明.
- 对心血管基因组学现状的审查,包括药物基因组学和多基因风险得分.
- 倡导研究人员,临床医生和政策制定者之间的多学科合作.
主要成果:
- 确定了心血管疾病遗传检测的关键政策领域.
- 强调对生物银行和基因组研究进行战略投资的必要性.
- 突出了人工智能和心血管基因组学的精确公共卫生潜力.
结论:
- 更新政策对于确保心血管基因组学公平获取,适当监督和道德数据管理至关重要.
- 需要采用多学科的方法来充分利用遗传和基因组测试在心血管保健中的潜力.
- 战略投资和研究对于推进变异解释和改进风险预测模型至关重要.
相关概念视频
Genome-wide Association Studies-GWAS
12.6K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
12.6K
Principles of Pharmacogenetics: Types of Genetic Variants
138
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
138
Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Coronary Artery Disease I: Introduction
1.8K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Cardiomyopathy I: Introduction and Classification
826
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
826
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
948
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
948


